海外の治験の状況「1」での検索結果
10032件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- A study for efficacy and safety of Camrelizumab combined with Famitinib Malate Capsules in the second-line treatment of advanced non-small cell lung cancer
- Advanced non-small cell lung cancer
- China
- 2019-10-16
Not Recruiting
- Efficacy and Safety of Anlotinib Combined with Chemotherapy Versus Anlotinib Alone in the Third-line Treatment of Advanced Non-small Cell Lung Cancer
- lung cancer
- China
- 2019-10-27
Not recruiting
- Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
- Advanced Ovarian Cancer
- Taiwan
- 2019-10-19
Not Recruiting
- Effects of dietary sodium restriction and mineralocorticoid receptor antagonist in patients with Chronic kidney disease stages 1~3: a randomized controlled trial
- chronic kidney disease
- China
- 2019-10-28
Recruiting
- A study on the characteristics of Korean type 2 diabetes mellitus patients suitable for the treatment of GLP-1 agonist
- ;Endocrine, nutritional and metabolic disease
- Korea, Republic of
- 2019-10-24
Recruiting
- A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
- HIV-1 Infection
- Russian Federation
- 2019-10-22
Not recruiting
- SHR0302 and Steroid as First Line Therapy for Chronic GVHD
- Chronic GVHD
- China
- 2019-10-25
Not Recruiting
- Phase II clinical study of Sintilimab for consolidation therapy after first-line chemotherapy for advanced lung squamous cell carcinoma
- Lung cancer
- China
- 2019-11-03
Not Recruiting
- Phase II clinical study for Sintilimab (IBI308) in the maintenance therapy after second-line chemoradiotherapy for local and/or regional recurrent esophageal squamous cell cancer patients
- esophageal cancer
- China
- 2019-11-02
Not Recruiting
- The comparative study of 7 and 14 days bismuth-containing quadruple therapy as first line therapy for eradication of clarithromycin-resistant Helicobacter pylori
- ;Diseases of the digestive system
- Korea, Republic of
- 2019-11-01
Not Recruiting
- Prospective, single-center, observational clinical study for Camrelizumab in the second-line treatment of advanced EGFR and ALK wild-type non-small cell lung cancer
- non-small cell lung cancer
- China
- 2019-11-05
Not recruiting
- Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
- Biliary Tract Adenocarcinoma
- China
- 2019-11-06
Not Recruiting
- Apatinib mesylate tablets combined with nab-paclitaxel in the second-line treatment of advanced gastric cancer:a single-arm, multicenter,prospective phase II study
- Advanced gastric cancer
- China
- 2019-11-12
Recruiting
- A Phase II Study of Sintilimab Combined With Docetaxel as Second-line Therapy in NSCLC Patients
- Non-small cell lung cancer
- China
- 2019-11-22
Recruiting
- Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
- Advanced Gastric Cancer
- China
- 2019-11-27
Not Recruiting
- A trial of trastuzumab-pkrb combined with modified FOLFOX-6 in Biliary tract cancer patients progressed on first line therapy
- ;Neoplasms
- Korea, Republic of
- 2019-11-15
Not Recruiting
- change of infection after disinfection of ECMO herb and line with 237; chlorohexidine
- ;Diseases of th respiratory system
- Korea, Republic of
- 2019-11-13
Not Recruiting
- Safety and efficacy study of Sintilimab combined with IBI305 and mFOLFOX4 in first-line treatment of advanced hepatocellular carcinoma
- Hepatocellular carcinoma
- China
- 2019-12-08
Not Recruiting
- A Phase II Study for Exploring the Efficacy and Safety of Toripalimab with Anlotinib for Second- or third-line treatment of EGFR-TKI-resistant Patients with Advanced Non-squamous Non-small Cell Lung Cancer.
- lung cancer
- China
- 2019-12-12
Recruiting
- GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
- Metastatic Gastric Cancer
- Korea, Republic of
- 2018-11-21